(atc: A04aa02), Only the pharmaceutical form fta; 3.
, tropisetron and dolasetron have similar pharmacological properties.
SUSTOL is the first approved therapy that utilises the company's Biochronomer polymer-based drug delivery technology, allowing it to maintain therapeutic levels of granisetron
for >=5 days, covering both the acute and delayed phases of CINV.
Since NK1 receptor antagonists are used in combination with 5-HT3 receptor antagonists, CINVANTI offers a strong strategic and operational fit with Heron's existing commercial product, SUSTOL[R], our extended-release, injectable product that incorporates the 5-HT3 receptor antagonist granisetron
and is also indicated for the prevention of CINV.
More recently, a pharmacotherapy trial investigated the use of granisetron
to treat sexual dysfunction associated with antidepressant use in female patients diagnosed with depression.
APF530 contains the 5-HT3 antagonist granisetron
formulated in the Company's proprietary Biochronomer[TM] drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.
Breckenridge also launched anastrozole (Arimidex), bicalutamide (Casodex), granisetron
(Kytril), hydrocortisone enema (Cortenema), letrozole (Femara), neomycin tablets and terbinafine (Lamisil) in the last year and recently received approval for levetiracetam tablets, which it plans to launch soon.
The recent European approval of Archimedes' innovative fentanyl pectin nasal spray product for of breakthrough cancer pain (PecFent) is one example of a product specifically designed for purpose and there are numerous other nasal drugs in clinical development at Archimedes and elsewhere, including granisetron
(nausea/vomiting), diazepam and midazolam (seizures), testosterone (hypogonadism) and apomorphine (Parkinson's disease).
Hence we have performed a double blind, randomized controlled trial to compare the relative efficacies of ondansetron, granisetron
and palonosetron for both acute and delayed onset emesis, in moderately and highly emetogenic chemotherapy against their respective prices in Indian market.
transdermal system (Sancuso[R]) is the first transdermal medication indicated for use in chemotherapy-induced nausea and vomiting.
One of the newest class of antiemetics, known as the serotonin agents or as the 5-HT3antagonists, includes dolasetron (Anzemet[R]), granisetron
(Kytril[R]), ondansetron (Zofran[R]), and palonosetron (Aloxi[R]).
(Kytril, marketed by Hoffmann-La Roche Inc.